Status:
COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Huntington's Disease
Eligibility:
All Genders
25+ years
Phase:
PHASE2
Brief Summary
This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.
Eligibility Criteria
Inclusion
- Key
- Must have completed dosing in ISIS 443139-CS1
- Key
Exclusion
- Any new condition or worsening of existing condition that could make the patient unsuitable for participation or interfere with the patient participating in and/or completing the study
Key Trial Info
Start Date :
January 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 8 2019
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT03342053
Start Date
January 2 2018
End Date
October 8 2019
Last Update
March 24 2022
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of British Columbia; The Centre for Huntington Disease
Vancouver, British Columbia, Canada, V6T 2B5
2
Charité - Universitätsmedizin Berlin, Campus Charité Mitte; Klinik für Psychiatrie und Psychotherapi
Berlin, Germany, 10117
3
St. Josef and St. Elisabeth GmbH ; Klinikum Bochum, Zentralapotheke
Bochum, Germany, 44791
4
Universitaetsklinikum Ulm
Ulm, Germany, 89081